102 related articles for article (PubMed ID: 17304086)
1. Use of the U.S. and U.K. scoring algorithm for the EuroQol-5D in an economic evaluation of cardiac care.
Shrive FM; Ghali WA; Johnson JA; Donaldson C; Manns BJ
Med Care; 2007 Mar; 45(3):269-73. PubMed ID: 17304086
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of sirolimus-eluting stents.
Shrive FM; Manns BJ; Galbraith PD; Knudtson ML; Ghali WA;
CMAJ; 2005 Feb; 172(3):345-51. PubMed ID: 15684117
[TBL] [Abstract][Full Text] [Related]
3. Comparison of FACT- and EQ-5D-based utility scores in cancer.
Pickard AS; Ray S; Ganguli A; Cella D
Value Health; 2012; 15(2):305-11. PubMed ID: 22433762
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysis.
Brunner-La Rocca HP; Kaiser C; Bernheim A; Zellweger MJ; Jeger R; Buser PT; Osswald S; Pfisterer M;
Lancet; 2007 Nov; 370(9598):1552-9. PubMed ID: 17980734
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
6. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.
Ariza-Ariza R; Hernández-Cruz B; Carmona L; Dolores Ruiz-Montesinos M; Ballina J; Navarro-Sarabia F;
Arthritis Rheum; 2006 Oct; 55(5):751-6. PubMed ID: 17013822
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the EuroQol and short form 6D in Singapore multiethnic Asian knee osteoarthritis patients scheduled for total knee replacement.
Xie F; Li SC; Luo N; Lo NN; Yeo SJ; Yang KY; Fong KY; Thumboo J
Arthritis Rheum; 2007 Aug; 57(6):1043-9. PubMed ID: 17665466
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease.
van Stel HF; Buskens E
Health Qual Life Outcomes; 2006 Mar; 4():20. PubMed ID: 16563170
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
[TBL] [Abstract][Full Text] [Related]
10. Predicting EQ-5D utility scores from the Seattle Angina Questionnaire in coronary artery disease: a mapping algorithm using a Bayesian framework.
Wijeysundera HC; Tomlinson G; Norris CM; Ghali WA; Ko DT; Krahn MD
Med Decis Making; 2011; 31(3):481-93. PubMed ID: 21127316
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the EQ-5D-3L and ICECAP-O in an older post-acute patient population relative to the general population.
Couzner L; Crotty M; Norman R; Ratcliffe J
Appl Health Econ Health Policy; 2013 Aug; 11(4):415-25. PubMed ID: 23807538
[TBL] [Abstract][Full Text] [Related]
12. Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer.
Lien K; Tam VC; Ko YJ; Mittmann N; Cheung MC; Chan KK
Curr Oncol; 2015 Dec; 22(6):e443-52. PubMed ID: 26715881
[TBL] [Abstract][Full Text] [Related]
13. Choosing between measures: comparison of EQ-5D, HUI2 and HUI3 in persons with hearing complaints.
Grutters JP; Joore MA; van der Horst F; Verschuure H; Dreschler WA; Anteunis LJ
Qual Life Res; 2007 Oct; 16(8):1439-49. PubMed ID: 17647093
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary artery disease and abnormal fractional flow reserve.
Fearon WF; Shilane D; Pijls NH; Boothroyd DB; Tonino PA; Barbato E; Jüni P; De Bruyne B; Hlatky MA;
Circulation; 2013 Sep; 128(12):1335-40. PubMed ID: 23946263
[TBL] [Abstract][Full Text] [Related]
15. Preliminary report on a cost-utility analysis of revascularization by percutaneous coronary intervention for ischemic heart disease.
Takura T; Tachibana K; Isshiki T; Sumitsuji S; Kuroda T; Mizote I; Ide S; Nanto S
Cardiovasc Interv Ther; 2017 Apr; 32(2):127-136. PubMed ID: 27230087
[TBL] [Abstract][Full Text] [Related]
16. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
Eisenstein EL; Wijns W; Fajadet J; Mauri L; Edwards R; Cowper PA; Kong DF; Anstrom KJ
JACC Cardiovasc Interv; 2009 Dec; 2(12):1178-87. PubMed ID: 20129543
[TBL] [Abstract][Full Text] [Related]
17. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?
Rutten-van Mölken MP; Oostenbrink JB; Tashkin DP; Burkhart D; Monz BU
Chest; 2006 Oct; 130(4):1117-28. PubMed ID: 17035446
[TBL] [Abstract][Full Text] [Related]
18. [Cost-utility analysis of percutaneous coronary intervention in 13 cities of China].
Song XT; Du MY; Yuan F; Lü SZ;
Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Jun; 38(6):484-7. PubMed ID: 21033126
[TBL] [Abstract][Full Text] [Related]
19. A comparison of EQ-5D index scores derived from the US and UK population-based scoring functions.
Nan Luo ; Johnson JA; Shaw JW; Coons SJ
Med Decis Making; 2007; 27(3):321-6. PubMed ID: 17545501
[TBL] [Abstract][Full Text] [Related]
20. EQ-5D versus SF-12 in coronary patients: are they interchangeable?
De Smedt D; Clays E; Annemans L; De Bacquer D
Value Health; 2014; 17(1):84-9. PubMed ID: 24438721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
